Enhancing Scale-Up, Increasing Quality, and Reducing Costs for AVs, LVVs, AAVs and More The 3rd Viral Vector Process Development and Manufacturing Summit returns to Boston, uniting industry leaders ...

As lentiviral vector (LVV) programs advance toward larger clinical trials and commercialization, manufacturing platforms and ...

Effective process development for viral vector-based medicines is paramount for optimized process efficiency, robustness, scalability, and product quality. Well-designed processes streamline ...

Genezen has opened its new process development and analytical lab for viral vector production. Genezen, a cell and gene therapy contract development and manufacturing organization, has officially ...

Pharmaceutical Technology spoke with Tania Pereira Chilima, Deputy CTO at Univercells Technologies about their technology and how it can be used in viral vector manufacturing, which is needed for ...

Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...

With the FDA’s fast-evolving quality assessment and lack of standard guidance, and the continued challenge of viral vector recovery yield and purity, the 2nd Viral Vector Process Development & ...